FOR EAEU PHARMA PARTNERS
Exclusive regional rights to de-risked, near-approval assets
Fund a confirmatory trial on a drug that already has real efficacy data and an FDA-recognized path — and secure exclusive EAEU commercial rights before the rest of the world catches on.
Why fund someone else’s confirmatory trial
Every asset AllianceXPartners brings to an EAEU partner has already cleared the hardest part: a full pivotal trial, a real (if partial) efficacy signal, and enough regulatory engagement to know what a confirmatory trial needs to show. That is a fundamentally different risk profile from funding drug discovery from scratch. Your capital goes toward finishing a trial on a molecule with known human safety data and a defined path to approval — not toward years of preclinical uncertainty.
In exchange for funding the trial, you receive exclusive commercial rights across EAEU markets to a drug that, on a positive readout, is simultaneously advancing toward US FDA approval. You are not betting on the science alone; you are funding the single trial that both markets need.
What you get
Exclusive EAEU rights
Sublicensed directly from the originator biotech, structured and enforced by AXP.
Local regulatory sponsorship
Your role in the trial structure supports mutual-recognition or decentralized EAEU registration.
A managed, compliant trial
Run through our clinical site management network to ICH-GCP standard, with sanctions-aware fund and data routing from day one.
One trial, cleared for both markets
Every AXP-structured trial is designed as a single multi-regional study with a compliant, two-track site footprint — so the dataset you fund supports EAEU registration in parallel with the US FDA sub-population filing. That means the drug you’re bringing to your market is, on the same timeline, advancing toward the world’s largest pharmaceutical market too — a strong signal of quality and value for the asset you now control regionally. See how the two-track model works.
AllianceXPartners 